Kalir Erez 4

What Happened
Kalir Erez, a director of Vor Biopharma, was granted a derivative award of 57,162 shares on June 11, 2026. The reported acquisition price is $0.00 per share (the filing records this as a derivative grant, not an open‑market purchase), so the filing shows $0 cash exchanged.

Key Details

• Transaction date: June 11, 2026; Form 4 filed June 12, 2026 (timely filing in this report).
• Transaction type/code: Award/Grant (A); classified as a derivative security.
• Shares granted: 57,162; reported price: $0.00; reported cash value: $0.
• Shares owned after transaction: Not specified in the provided excerpt of the filing.
• Notable footnote: Vesting schedule — “One thirty‑sixth of the shares subject to the option shall vest and become exercisable on July 11, 2026 and each month thereafter, subject to continued service” (i.e., monthly vesting over 36 installments, subject to service).
• No 10b5‑1 plan, tax‑withholding, or cashless exercise noted in the provided details.

Context
This was a grant of a derivative award (likely options or RSUs as recorded on the Form 4) rather than a market purchase or sale; no immediate sale or cash transaction is reported. Such awards are commonly used for director compensation and do not by themselves indicate a buy/sell market signal.